Biopharmaceutical company Molecular Targeting Technologies (MTTI) has received a patent from the U.S. Patent and Trademark Office for its F-18 fluoroglucaric acid (F-18 FGA) PET necrosis imaging agent.
U.S. Patent No. 10,953,113 covers a five-minute quantitative conversion of F-18 FDG to F-18 FGA, according to the vendor. Specific for dead cells, the F-18 FGA agent is designed for use in monitoring tumor response to therapy, and it could also be utilized in applications such as tracking organ fibrosis in chronic kidney disease and liver fibrosis, as well as in detecting myocardial infarction and stroke, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
